IFFIm newsletters
IFFIm newsletters
Access all IFFIm newsletters
December 2024
IFFIm finances Gavi’s groundbreaking malaria vaccine programme; how sukuks diversified IFFIm’s investor base and portfolio; interview with IFFIm Board member Jeff Diehl; interview with IFFIm Board member Eila Kreivi: mobilising resources to save lives.
View UpdateNovember 2024
IFFIm issues record-breaking $1 billion bond, raising immediate funding for Gavi and CEPI; G7 group endorses IFFIm; Rachel Turner reflects on IFFIm and Gavi; IFFIm: a unicorn or a road map?; IFFIm earns A+ rating from the UK for the sixth consecutive year, solidifying its role in Gavi’s global immunisation efforts; IFFIm's Board attends key meetings in Washington; Fitch affirms IFFIm's rating at 'AA-'.
August 2024
Strengthening Gavi’s replenishment with IFFIm; Lifesaving immunisation made possible by IFFIm; IFFIm has provided more than US$ 21.6 million to Gavi for its malaria programme of the US$ 49 million spent to deliver the malaria vaccine in 14 countries so far; IFFIm’s Board of Directors welcomes three new members; Fitch Revises IFFIm's Outlook from negative to Stable; Affirms at 'AA-‘.
April 2024
"Pure play" Environmental, Social and Governance bonds have arrived in the bond market; a Nigerian's campaign for the HPV jab is a fight against more than cancer; IFFIm welcomes Augustin Flory; IFFIm Board meets in London with eye on Gavi replenishment; Donors set sights on IFFIm’s upcoming role in Gavi replenishment; Fitch Improves IFFIm's Outlook to Stable; Affirms at 'AA-‘.
IFFIm Update - December 2023
HPV vaccinations rebound in 2023; Doris Herrera-Pol steps down after eight years on the IFFIm Board; Why aren’t there more IFFIms; IFFIm and Gavi prepare for future global emergencies; IFFIm year in review.
November 2023
IFFIm earns an A+ rating from FDCO; how the meningitis vaccine works; Gavi report highlights rebound in routine immunisation; IFFIm funding helps #VaccinesWork; IFFIm donors gather for annual meeting, IFFIm ratings.
August 2023
IFFIm takes the spotlight at Gavi’s Raising Generation ImmUnity conference; IFFIm: past, present and future; Gavi milestone: one billion children immunised; 4% too many: Nepal sets its sights on finding and protecting its cohort of unvaccinated kids; Board Members crisscross Europe to highlight IFFIm’s impact and future potential; IFFIm Board meets in Geneva with focus on pandemic preparedness.
April 2023
Mentors, mothers and mavens: the women who inspired IFFIm’s Board members; Canada pledges C$ 125 million to IFFIm; How IFFIm funding helps #VaccinesWork; IFFIm's Board charts plans for 2023.
IFFIm Update - December 2022
IFFIm funding contributes to health gains across Africa; HPV vaccines introduced in four new countries, aided by IFFIm funding; women health workers navigate distance and misinformation to deliver vaccines; how IFFIm ha made a difference for Gavi.
October 2022
How the World Bank built trust in IFFIm bonds; IFFIm returns to market with US$ 500 3-year bond; the Ugandan nurse going the extra mile; reaching zero-dose children in Chad’s nomadic community; Bangladesh’s success in dealing with COVID-19; Gavi Annual Progress Report: 2021 was “defining” for IFFIm; IFFIm Board meets in Washington.
July 2022
IFFIm issues £250 million vaccine bond; Reaching zero dose children in the remote Himalayas; The boat doctors vaccinating in India's Sundarbans; Lesotho mothers welcome the reintroduction of HPV vaccine; Kenya pushes back yellow fever outbreaks; IFFIm Board meets in Geneva; “Follow the Money” study cites IFFIm as success story.
April 2022
IFFIm "essential" to continued financing for the Gavi COVAX AMC; Reaching zero dose children in the remote Himalayas; Nepalese health workers go the distance to deliver vaccines; COVAX AMC update, IFFIm earns an ‘A+’ rating; Ken Lay speaks at Wilton Park; Guarantee Facility makes US$ 225 million in revolving funds available to Gavi; IFFIm’s Board meets in London.
December 2021
IFFIm raises US$ 1 billion as vaccine bonds heat up capital markets; country health systems adapt to handle COVID-19 vaccine rollout; interviews with board members Hassatou N’Sele, Monique Barbut and Ingrid van Wees; IFFIm celebrates 15 years of vaccine bonds.
November 2021
IFFIm increases April 2026 vaccine bond by US$ 250 million to total US$ 1 billion; IFFIm turns 15; training dogs to sniff out COVID-19.
July 2021
COVAX begins vaccine rollout amid global supply challenges; Sterling K. Brown interviews Dr Seth Berkeley about COVID-19 vaccines; IFFIm welcomes Monique Barbut, Hassatou N’Sele and Ingrid van Wees to the Board of Directors; Australia increases support for COVAX; Vaccine Bonds are helping defuse the pandemic; sustainability bonds have bridged the vaccine funding gap for poorer countries.
May 2021
IFFIm helps COVAX bring fair, global access to COVID-19 vaccines; Fatimatou Zahra Diop is a trailblazer for women in finance and vaccine access; Board Chair Ken Lay talks about his career and goals for IFFIm; IFFIm returns to the market with $750 million vaccine bonds that will provide funding for Gavi’s core programmes as well as the Gavi COVAX Advance Market Commitment; Sweden and Italy pledge support; video story shows the first COVAX deliveries.
Previous editions
October 2020
Donors secure IFFIm’s future strength with $926 million in new pledges; IFFIm helps Gavi respond to COVID-19; Gavi prioritises health system strengthening; Marcus Fedder discusses his work on the Board; new Board member Jessica Pulay introduces herself in a Q and A; IFFIm supports new typhoid vaccines; Board members discuss IFFIm in the news; IFFIm Vaccine Bond named 2019 “Deal of the Year;” Gavi and EIB design new Guarantee facility; humanitarian finance professionals launch IHFF forum.
30 October 2019
Vaccine Bonds fund CEPI’s fight against epidemics; In Japan, Gavi launches its journey to 2020 Replenishment Conference; Islamic investors make a positive impact on global health with Vaccine Sukuks; Flexible funding helps Gavi respond to Ebola outbreak; The Edge of innovative finance; “Life is about learning, earning and returning”; How Japanese investors primed a global market for vaccine bonds.
19 December 2018
IFFIm measures up; Gavi mid-term review in UAE assesses past progress, charts future path; Board Chair Cyrus Ardalan talks about IFFIm’s vision for socially responsible investing and its positive impact on Gavi; Gavi extends its IFFIm-funded polio vaccine campaign in Nigeria; IFFIm 2017 bond issuance generates US$ 300 million for vaccines; Bertrand de Mazières offers IFFIm extraordinary experience with social impact investing; Brazil’s US$ 20 million for IFFIm shows commitment to global immunisation
16 October 2017
IFFIm returns to international U.S. dollar benchmark market with its 2016 issuance; In Côte d’Ivoire, immunisation rebounds; IFFIm looks to the future with four initiatives; Gavi shapes the vaccine market to save more lives; Former IFFIm board member reflects on evolution of socially responsible investing.
01 August 2016
Approaching 10 years, IFFIm looks back — and ahead; IFFIm issues second Sukuk, raises US$ 200 million; Senegal spotlight: IFFIm’s impact on penta, pneumo and HSS; IFFIm helps make vaccines more affordable; IFFIm supports health system strengthening in Pakistan and Nepal; A growing recognition of IFFIm as model for other development sectors; A lifetime in development finance: IFFIm’s newest board member, Doris Herrera-Pol.
01 August 2015
With IFFIm support, 5-in-1 vaccine in all 73 Gavi countries; IFFIm makes debut in the Islamic finance market; IFFIm-funded vaccines protect children in Niger from leading causes of death; IFFIm helps make vaccines more affordable; Donors pledge support for Gavi and IFFIm in Berlin; IFFIm’s role in rebuilding health in Ebola affected countries; IFFIm Board welcomes Fatimatou Zahra Diop.
01 August 2014
IFFIm funded vaccines reach the hardest to reach in Afghanistan; IFFIm plays vital role in Gavi’s replenishment; Immunisation in Nigeria: mobilising a nation for child survival, with the help of IFFIm; How an investment banker put his skills to work in global health; Vaccine Bonds: saving lives and generating returns for investors.
12 July 2013
Innovative Finance Newsletter 8: July 2013 IFFIm disbursements for pentavalent now US$ 1.17 billion How the ‘walkers’ of the Haitian mountains deliver vaccines, with the help of IFFIm Keeping kids healthy and alive is not so easy in the tiny Haitian mountain village of Taillefer.
07 August 2012
Innovative Finance Newsletter 7: August 2012 Cost, maturity point to strong market return IFFIm raises US$ 137 million, boosting GAVI’s efforts to immunise a quarter billion children IFFIm made a strong return to the capital markets this summer, raising US$ 137 million with two appearances in the Japanese “uridashi” retail.
28 June 2011
An independent report has confirmed IFFIm's success in helping save additional lives. IFFIm continues to expand funding to support immunisation programmes in developing countries. Also, Australia has become IFFIm's ninth government donor and Brazil has also committed to joining.
01 June 2010
Funds provided by IFFIm from 2006 to the end of 2008 have helped save more than 3 million lives by accelerating access of immunisations to developing countries through GAVI Alliance. There is a high demand for vaccine bonds in Japan. Also, IFFIm has seen an expansion of new funding.
01 June 2009
Since 2006, IFFIm has raised more than US$ 2 billion on the international capital markets to support GAVI Alliance. The issue discusses the sterling debut bringing in £266 million; the Pope being recogned as IFFIm's first investor; and the continued success of vaccine bonds in Japan.
01 June 2008
This issue highlights the success of vaccine bonds in Japan. IFFIm continues to build on present success with its goal to raise US$ 4 billion for immunisation between 2006 and 2015.
01 November 2007
This issue assesses IFFIm's impact one year after its inception. 90% of approved funds scheduled for disbursement before the end of 2007.
01 April 2007
This issue highlights impressive initial results following the launch of IFFIm. Also, the update covers health systems strengthening; stockpiles; results from IFFIm funding; and IFFIm's first bond issuance.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.